



To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 14.08.2025

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting for the quarter 30.06.2025 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Thursday, the 14th day of August, 2025 at 04.30 P.M. at registered office of the Company for the quarter ended 30th June, 2025 considered and approved the following:

1. Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025. **(Enclosed as Annexure I).**
2. Limited Review Report (Standalone and Consolidated) for the quarter ended 30th June, 2025. **(Enclosed as Annexure II).**
3. Resignation of Mrs. Ankita Mathur as an Additional Director (Executive Category), of the Company w.e.f. 14.08.2025. **(Details provided in Annexure- A).**
4. Approve the closure of Bahrain Office. This strategic withdrawal from the Middle East market is not expected to have a material impact on the Company's consolidated financial statements, as operations in the region were in an early-stage phase, with negligible revenue contribution and minimal influence on the Company's overall performance. **(Details provided in Annexure- B).**
5. Discussed on the order passed by the Securities Exchange Board of India ("SEBI") i.e. issuing penalty and directions to the Directors of the Company and considered proposal to seek legal advise and take an appropriate course of action by exploring options including approval to appeal in the Securities Appellate Tribunal (SAT) and authorized the Directors to do the needful. **(In continuation with the Disclosure under Regulation 30 of SEBI LODR intimated to the exchange on 12.08.2025) (Details provided in Annexure- C).** The recent order issued by SEBI does not have any material impact on the company's core operations or financial stability. While the company continues to operate smoothly and remains focused on its strategic objectives certain aspects of the company's expansion plans may face recalibration, these adjustments are expected to be temporary and are not anticipated to affect the long-term growth trajectory.



**DECIPHER
LABS LIMITED**

Regd.Off: A-2, Q2, 5th Flr, Cyber Towers, Hitech City, Madhapur, Hyderabad, 500081 TS
Works: 9-109/9, Plot No.112, Road No. 14, Gayatri Nagar, Bouduppall, Hyderabad - 500 039
Ph: (+91)-40-29323151 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com
DLNo.TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

The meeting concluded at 06:20 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully
For Decipher Labs Limited

Sushant Mohan Lal
Non-Executive Director
(DIN- 01227151)

Encl. as above



Annexure A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A, Point 7 of Annexure 18 of Chapter V Section V-A of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Resignation of Mrs. Ankita Mathur as the Additional Director (Executive Category) of Decipher Labs Limited

Particulars	Details/ Information of such event(s)
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation Mrs. Ankita Mathur has tendered her resignation from the position of Additional Director (Executive Category) of the Company vide her letter dated 14.08.2025 due her other pre-occupations and personal reasons.
Date of appointment & Terms of appointment	She was relieved from the services of the Company with effect from 14.08.2025.
Brief Profile	Not Applicable
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
Directorships / memberships in other listed entities	Nil



Annexure B

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A, Point 7 of Annexure 18 of Chapter V Section V-A of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

date of such binding agreement, if any, entered for sale of such unit/division, if any;	There are no binding agreements.
amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year	Negligible turnover.
date of closure or estimated time of closure;	Estimated to close completely in 30 days.
reasons for closure.	Geopolitical reasons to avoid risk



Annexure -C

Details regarding the further course of action to be taken by the Company

Particulars	Details
Name of the Authority	The order was passed by the Securities Exchange Board of India (SEBI)
Nature and details of the Action(s) taken or order(s) passed	As provided in the Disclosure filed by the Company dated 12.08.2025
Course of Action decided by the Board of Directors	The Board has decided to explore various available options and seek opinions from professionals on proper course.
Impact om Financial, operational or other activities of the listed entity	There is no impact on the financial, operational, other activities of the Company due to levy of penalties or other directions

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd. off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Unaudited Standalone Financial Results For the Quarter Ended 30th June, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	84.65	22.60	38.34	85.32
II. Other income	-	0.01	0.17	2.28
III. Total Income (I + II)	84.65	22.61	38.51	87.60
IV. Expenses				
Purchase of Stock in trade	64.10	23.00	29.25	67.25
Changes in inventories of stock in trade	-	-	-	-
Employee Benefits Expense	3.85	8.30	7.72	23.43
Finance Costs	-	-	-	-
Depreciation expense	0.45	0.45	0.32	1.67
Other expenses	10.22	7.30	13.83	39.14
Total expenses	78.62	39.05	51.12	131.49
V. Profit/(Loss) before Exceptional items (III - IV)	6.03	(16.45)	(12.61)	(43.90)
VI. Exceptional items	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	6.03	(16.45)	(12.61)	(43.90)
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.44	(0.37)	0.47	(0.13)
IX. Profit/(Loss) for the period (VII-VIII)	5.59	(16.81)	(13.08)	(44.02)
X. Other comprehensive income	-	-	-	-
XI. Total comprehensive income for the year	5.59	(16.81)	(13.08)	(44.02)
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share				
(1) Basic	0.06	(0.17)	(0.13)	(0.44)
(2) Diluted	0.06	(0.17)	(0.13)	(0.44)

Notes

1. The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	67.50	22.60	30.00	68.60
b) Consultancy Services	17.15	-	8.34	16.72
Total Sales	84.65	22.60	38.34	85.32
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	84.65	22.60	38.34	85.32
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	4.81	(15.16)	(9.87)	(35.29)
b) Consultancy Services	1.22	(1.28)	(2.74)	(8.60)
Total	6.03	(16.45)	(12.61)	(43.90)
Less: Interest and exceptional items	-	-	-	-
Total Profit before tax	6.03	(16.45)	(12.61)	(43.90)
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	999.00	913.55	900.13	913.55
b) Consultancy Services	4.28	4.27	8.34	4.27
Total Assets	1,003.28	917.82	908.47	917.82
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	148.96	69.09	28.79	69.09
b) Consultancy Services	-	-	-	-
c) Unallocated liabilities	-	-	-	-
Total Liabilities	148.96	69.09	28.79	69.09

2. The above results for the quarter ended 30th June 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th August 2025.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure

For and on behalf of the Board



Sushant Mohan Lal

Sushant Mohan Lal
Non Executive Director
DIN: 01227151

Place: Hyderabad
Date: 14.08.2025

Decipher Labs Limited. (CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Audited Consolidated Financial Results For the Quarter Ended June 30, 2025

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	292.37	350.01	744.10	2,261.24
II. Other income	1.12	87.05	15.81	131.82
III. Total revenue (I + II)	293.49	437.06	759.91	2,393.07
IV. Expenses				
Purchase of Stock-in-Trade	64.10	23.00	29.25	67.25
Employee benefits expense	472.61	376.27	511.35	2,139.16
Finance costs	-	-	-	-
Depreciation and amortisation expense	11.71	12.65	11.28	47.63
Other expenses	87.30	608.34	72.24	777.65
Total expenses	635.72	1,020.26	624.12	3,031.69
V. Profit/(Loss) before Exceptional item (III - IV)	(342.23)	(583.20)	135.79	(638.62)
VI. Exceptional items	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	(342.23)	(583.20)	135.79	(638.62)
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.44	(172.59)	41.13	(130.60)
IX. Profit/(Loss) for the period (V-VI)	(342.67)	(410.61)	94.66	(508.02)
X. Other comprehensive income				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	28.45	2.24	(0.24)	52.38
XI. Total comprehensive income for the year	(314.22)	(408.37)	94.42	(455.64)
Net Profit/(Loss) for the year attributable to:				
Owners of the parent	(342.67)	(410.61)	94.66	(508.02)
Non-Controlling Interests	-	-	-	-
Other Comprehensive Income attributable to:				
Owners of the parent	28.45	99.65	94.42	52.38
Non-Controlling Interests	-	-	-	-
Total Comprehensive Income attributable to:				
Owners of the parent	(314.22)	(408.37)	94.42	(455.64)
Non-Controlling Interests	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share				
(1) Basic	(3.39)	(4.07)	0.94	(5.03)
(2) Diluted	(3.39)	(4.07)	0.94	(5.03)

Notes

1. The operations of the Group relate to two segments viz; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31st March, 2025
	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	67.50	22.60	30.00	68.60
b) Consultancy Services	224.87	327.41	714.10	2,192.65
Total Sales	292.37	350.01	744.10	2,261.24
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	292.37	350.01	744.10	2,261.24
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	4.80	0.76	5.47	(19.37)
b) Consultancy Services	(347.03)	(583.95)	130.32	(619.24)
Total	(342.23)	(583.19)	135.80	(638.61)
Less: Interest and exceptional item	-	-	-	-
Total Profit/(Loss) before tax	(342.23)	(583.19)	135.80	(638.61)
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	999.00	913.55	900.47	913.55
b) Consultancy Services	1,370.72	1,662.93	2,207.76	1,662.93
Total Assets	2,369.72	2,576.47	3,108.23	2,576.48
Segment liabilities				

a) Manufacturing and trading of Pharmaceutical drugs	148.96	69.09	28.79	69.09
b) Consultancy Services	346.53	221.82	798.93	221.82
Total Liabilities	495.49	290.91	827.72	290.91

2. The above results for the quarter ended 30th June 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th Aug 2025.
3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
4. The above results as of 30th June 2025 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Barhain.

For and on behalf of the Board



Sushant Mohan Lal
Non Executive Director
DIN: 01227151



Place: Hyderabad
Date: 14.08.2025



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Review Report to
The Board of Directors
Decipher labs Limited.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (the "Company") for the quarter ended 30th June 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)

K. Sreenivasan
Partner

Membership No.206421

UDIN: 25206421BMIWER5880

Place: Secunderabad

Date : 14.08.2025





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited ("the Holding Company") and its subsidiaries, (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the subsidiaries.
Decipher Software Solutions LLC, USA
Decipher Soft Middle East W.L.L Bahrain
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiary referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





6. We did not review the interim financial results of one subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs.208.84 lakhs, total net profit/(loss) after tax of Rs. (348.26) lakhs and total comprehensive Income of Rs. (0.08) lakhs for the quarter ended 30th June 2025, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.0029345)

K.Sreenivasan

Partner

Membership No.206421

UDIN: 25206421BMIWES6497

Place : Secunderabad

Date : 14.08.2025



Date: 14-Aug-2025

To,
The Board of Directors,
Decipher Labs Limited,
A-2, Q2, 5th Floor, Cyber Towers,
Hitech City, Madhapur,
Hyderabad, Telangana, 500081

Sub: Resignation as Additional Director (Executive Category) w.e.f. 14.08.2025

I hereby tender my resignation from the position of Additional Director (Executive Category) with effect from 14.08.2025 due to other pre-occupations and personal reasons.

I take this opportunity to thank my colleagues on the Board for their continued support and wish them and Company a great success in all their endeavors.

Thanking you,
Yours faithfully,



Ankita Mathur
(DIN: 05329604)